| Literature DB >> 30538804 |
Maura Calvani1, Lorenzo Cavallini1,2, Annalisa Tondo1, Valentina Spinelli3, Luisa Ricci2, Amada Pasha1,4, Gennaro Bruno1,4, Daniela Buonvicino4, Elisabetta Bigagli3, Marina Vignoli1,4, Francesca Bianchini5, Laura Sartiani3, Maura Lodovici3, Roberto Semeraro2, Filippo Fontani1,4, Francesco De Logu4, Massimo Dal Monte6, Paola Chiarugi5, Claudio Favre1, Luca Filippi7.
Abstract
The early phases of embryonic development and cancer share similar strategies to improve their survival in an inhospitable environment: both proliferate in a hypoxic and catecholamine-rich context, increasing aerobic glycolysis. Recent studies show that β3-adrenergic receptor (β3-AR) is involved in tumor progression, playing an important role in metastasis. Among β-adrenergic receptors, β3-AR is the last identified member of this family, and it is involved in cancer cell survival and induction of stromal reactivity in the tumor microenvironment. β3-AR is well known as a strong activator of uncoupling protein 1 (UCP1) in brown fat tissue. Interestingly, β3-AR is strongly expressed in early embryo development and in many cancer tissues. Induction of uncoupling protein 2 (UCP2) has been related to cancer metabolic switch, leading to accelerated glycolysis and reduced mitochondrial activity. In this study, for the first time, we demonstrate that β3-AR is able to promote this metabolic shift in both cancer and embryonic stem cells, inducing specific glycolytic cytoplasmic enzymes and a sort of mitochondrial dormancy through the induction of UCP2. The β3-AR/UCP2 axis induces a strong reduction of mitochondrial activity by reducing ATP synthesis and mitochondrial reactive oxygen species (mtROS) content. These effects are reverted by SR59230A, the specific β3-AR antagonist, causing an increase in mtROS. The increased level of mtROS is neutralized by a strong antioxidant activity in embryonic stem cells, but not in cancer stem cells, where it causes a dramatic reduction in tumor cell viability. These results lead to the possibility of a selective antitumor therapeutic use of SR59230A. Notably, we demonstrate the presence of β3-AR within the mitochondrial membrane in both cell lines, leading to the control of mitochondrial dormancy.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30538804 PMCID: PMC6258109 DOI: 10.1155/2018/6816508
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Figure 1β3-AR affects the glycolytic metabolism of both A375 melanospheres and embryonic stem cell. WB analysis of β3-AR, hexokinase II (HKII), monocarboxylate transporter-4 (MCT-4), and GLUT-1 markers (a). Analysis of the lactate export and glucose uptake (b). ATP production assay (c). A375 melanospheres and mouse ES cells treated with BRL37344 (10 μM) and BRL37344 (10 μM) + SR59230A (10 μM). The following experiments were performed: representative random figure of melanospheres in each condition and clonogenesis assay quantification (d); analysis of CD133+ cells by FACS and WB of stem cell marker SOX-2 (e); glucose uptake and lactate export in A375 melanospheres and ES cells (f, g); WB analysis of HKII and MCT-4 in A375 melanospheres (h) and ES cells (i). Data are representative of at least three experiments (mean and SD). ∗∗ P < 0.01 and ∗∗∗ P < 0.001.
Figure 2β3-AR/UCP2 axis blockade affects the glycolytic metabolism of both A375 and ES cells. Western blot analysis of UCP2 marker after treatment with BRL37344 (10 μM) + genipin (15 μM), BRL37344 (10 μM), and BRL37344 (10 μM) + SR59230A (10 μM) (a, e). Glucose uptake and lactate export assays (b, f). WB analysis of HKII and MCT-4 markers (c, g). ATP production assay (d, h). Data are representative of at least three experiments (mean and SD). P values for SR59230A treatment ∗ P < 0.05, ∗∗ P < 0.01, and ∗∗∗ P < 0.001. P values for genipin treatment: # P < 0.05, ## P < 0.01, and ### P < 0.001.
Figure 3The antioxidant ability promotes survival in embryo with respect to tumor. The A375 melanospheres and ES cells were treated as in Figure 1. MTT survival experiment on each condition (a, f), mitochondrial mtROS measurement (b, g), FRAP assay (c, h), WB analysis of SOD-2 antioxidant marker (d, i), and MTT survival experiment on each condition in the presence of 100 μM β-ME (e, j). Data are representative of at least three experiments (mean and SD). NS: not significant. P values for SR59230A treatment: ∗ P < 0.05, ∗∗ P < 0.01, and ∗∗∗ P < 0.001; P values for genipin treatment: # P < 0.05 and ## P < 0.01.
Figure 4Functional β3-AR in mitochondria: a new receptor for an old compartment. WB analysis of β3-AR on mitochondria proteins (a). Confocal representative images of β3-ARs, MitoTracker, and merge of both markers (b). ATP production measured on isolated mitochondria as in Figure 1(d). Ectopic ADP was added to the reaction mix (c). mtROS measured as in Figure 3(a) (d). Summary scheme of the study (e). Data are representative of at least three experiments (mean and SD). P values for SR59230A treatment: ∗ P < 0.05; P values for genipin treatment: # P < 0.05.